SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in France

SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in
France

SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin
Board: SCIE), a San Diego based medical device company, today announced that
it has established a distribution partnership in France through Medipartner, a
Paris based firm specializing in the marketing and distribution of innovative
gastrointestinal medical devices. The Company believes that building an
effective distribution network in France will also enhance sales in the
emerging North African and Middle Eastern markets due to their relationship
with France.

Michel Vaudry, SpectraScience's VP of Sales and Marketing, said, "We are
pleased to add Medipartner to our expanding distribution footprint throughout
Europe, and are optimistic that physicians and more importantly, patients in
France will greatly benefit from the introduction of WavSTAT to this market.
In terms of cancers plaguing France's population, colon cancer has one of the
highest rates of incidence and mortality."

Medipartner's Chief Executive, Christian Arnould, stated that, "We decided to
add the WavSTAT to products that we distribute because it is both innovative
and it will translate into progress for cancer detection. Our focus is in the
gastrointestinal market, and based on our experience and understanding of that
market, I think that the WavSTAT is a great fit for us, and our customers."
Medipartner is the French distributor for Sandhill Scientific, a leading
international GI diagnostics company based in Colorado.

"We are shipping a unit to France this week," added Vaudry. "I will be going
to France to assist Christian in making demonstrations of the WavSTAT to
physicians at several healthcare centers of excellence, including the Hospital
Edourard Herriot in Lyon, which has just been ranked as one of the 10 best
healthcare centers in the world by Newsweek magazine." In addition, Mr.
Vaudry noted that Lyon is the headquarters of the International Agency for
Research on Cancer (IARC), one of the most prestigious cancer research
facilities in operation today.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
involve risks and uncertainties that may cause SpectraScience's actual results
to differ materially from results discussed in forward-looking statements.
Readers are urged to carefully review and consider the various disclosures
made by SpectraScience in this news release, its most recent Form 10-K and in
SpectraScience's other reports filed with the Securities and Exchange
Commission ("SEC") that attempt to advise interested parties of the risks and
factors that may affect SpectraScience's business. These forward-looking
statements are qualified in their entirety by the cautions and risk factors
filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs,
develops, manufactures and markets spectrophotometry systems capable of
determining whether tissue is normal, pre-cancerous or cancerous without
physically removing tissue from the body. The WavSTAT Optical Biopsy System
uses light to optically scan tissue and provides the physician with an
immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for
the European Union, the WavSTAT System is the first commercially available
product that incorporates this innovative technology for clinical use. In
addition, the Company's LUMA(R) Cervical Imaging technology has received FDA
approval as an optical non-invasive system that is proven to more effectively
detect cervical cancer precursors than conventional methods available today.

Contact:

SpectraScience, Inc. Hayden
Communications Investor Relations

Jim Hitchin, Chief Executive Officer Todd Pitcher
(858) 847-0200 x 201 (858)-518-1387

http://www.spectrascience.com

SOURCE SpectraScience, Inc.

Communications, Jim Hitchin, Chief Executive Officer, SpectraScience, Inc.,
+1-858-847-0200, ext. 201; Investor Relations, Todd Pitcher, Hayden,
+1-858-518-1387